Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS
Compared with the high-dose GC-based regimens used in ALMS, voclosporin-based triple immunosuppressive therapy resulted in fewer AEs overall and greater and earlier reductions in proteinuria over the first 6 months of treatment. These data reinforce the feasibility of using low doses of GCs and MMF to treat LN when combined with voclosporin as a third agent.
Authors
- Kenneth Kalunian (ORCID: https://orcid.org/0000-0003-0261-3102)
- Maria Dall’Era (ORCID: https://orcid.org/0000-0001-7439-2316)
- Lucy S. Hodge
- Matt Truman
- Ernie Yap (ORCID: https://orcid.org/0000-0002-2799-2367)
- Anca Askanase (ORCID: https://orcid.org/0000-0003-4597-5023)
- Neil Solomons
Institutions
- University of California, San Francisco (US)
- University of California San Diego (US)
- Aurinia (Canada) (CA)
- Columbia University (US)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/lupus-2024-001319
- Citations
- 4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Biogen